Quest Diagnostics (NYSE:DGX) announced on Wednesday that it will roll out a rapid molecular lab test to detect the avian ...

Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S.

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been awarded several contracts by the U.S. Centers for Disease Control and Prevention ...

Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, and offers 2.0% dividend yield.

Laboratory operator Quest Diagnostics beat Wall Street estimates for third-quarter profit and revenue on Tuesday, helped by robust demand for its diagnostic tests.

Quest will introduce an immediate response molecular laboratory test to aid in the detection of avian influenza A H5 virus. The new multi-target molecular diagnostic test is intended for use in ...

StockNews.com upgraded shares of Quest Diagnostics (NYSE:DGX – Free Report) from a hold rating to a buy rating in a research report released on Thursday morning. Other equities research analysts have ...

Quest has developed a multi-target molecular test for avian influenza A H5 virus that it plans to make available by the end of October.

Oct 23 - Lab operator Quest Diagnostics (DGX.N), opens new tab said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and ...

What Happened: Kuppusamy's recent move involves selling 1,775 shares of Quest Diagnostics. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on ...

Quest Diagnostics reported strong third-quarter earnings driven by acquisitions, with revenue surpassing expectations, though ...